228 results
8-K
EX-10.4
DMKPQ
DMK Pharmaceuticals Corp
19 Oct 23
Entry into a Material Definitive Agreement
5:07pm
such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility.
(c) You may
8-K
EX-10.3
DMKPQ
DMK Pharmaceuticals Corp
19 Oct 23
Entry into a Material Definitive Agreement
5:07pm
procedure shall be your sole responsibility.
(c) You may not exercise your option, unless the tax withholding obligations of the Company and/or any
8-K
DMKPQ
DMK Pharmaceuticals Corp
19 Oct 23
Entry into a Material Definitive Agreement
5:07pm
to public, private equity backed, and start-up businesses. From 2000 to 2011, Mr. Cohen served in various leadership roles of increasing responsibility
DEFC14A
imgz cp69
12 Oct 23
Proxy in contested solicitation
4:22pm
PREC14A
29hly24 6bxsyj
2 Oct 23
Preliminary proxy with contested solicitation
4:49pm
8-K
EX-5.1
honcfj7ot ts
3 Aug 23
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
4:59pm
8-K
EX-1.1
9xw5ubk69ubsbt3
3 Aug 23
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
4:59pm
8-K
EX-10.1
ebcfmvqscmo1aq
3 Aug 23
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
4:59pm
8-K
EX-99.1
jpa3 07b07q
3 Aug 23
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
4:59pm
424B4
nlysw9xb7tq78
3 Aug 23
Prospectus supplement with pricing info
4:55pm
8-K
EX-10.2
pdc36
24 Jul 23
Entry into a Material Definitive Agreement
4:20pm